Treatment with Secretin and a Cholecystokinin-Like Peptide in Patients with Pancreatic Cancer

A Pilot Study

S. SteffensrudDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

H. ErichsenDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

P. RøyslandDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

T. B. HalvorsenDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

R. KleppDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

O. KleppDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

E. WünschDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

H. PetersenDepts. of Medicine, Surgery, Radiology, and Pathology, Trondheim Regional and University Hospital, Trondheim, Norway, and Max-Planck Institute of Biochemistry, Martinsried, FRG

show all

Abstract

Secretin and cholecystokinin (CCK) have trophic effects on the pancreas and may therefore have a place in the treatment of pancreatic cancer. The present study was performed to examine whether these hormones may cause harm in patients with pancreatic cancer receiving cytostatics. The cytostatics were 5-fluorouracil, adriamycin, and mitomycin C (FAM). Secretin plus Thr²⁸Nle³¹CCK25-33, in doses stimulating pancreatic secretion to about 60% of maximal, were given as a continuous 6-day intravenous infusion just before (four patients) or immediately after (five patients) starting treatment with FAM. Five patients received FAM only. When considering symptoms, laboratory findings, abdominal CT scans, and survival, no evidence was found that secretin and CCK may cause serious or unpleasant side effects in patients with pancreatic cancer receiving cytostatics.

Key words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Treatment with Secretin and a Cholecystokinin-Like Peptide in Patients with Pancreatic Cancer

A Pilot Study

Information for

Open access

Opportunities

Help and information

Treatment with Secretin and a Cholecystokinin-Like Peptide in Patients with Pancreatic Cancer

A Pilot Study

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature